Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 672 entries
View as:

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

Phase: N/A Priority: Normal
NCT ID: NCT00617305 Org: User:
Start: 04/30/08 End: 07/31/11 Due: 07/31/12

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02876796 Org: User:
Start: 08/31/15 End: 10/31/15 Due: 10/31/16

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Phase: N/A Priority: Normal
NCT ID: NCT02121795 Org: User:
Start: 05/06/14 End: 03/01/19 Due: 03/01/20

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02943460 Org: User:
Start: 11/29/16 End: 05/18/20 Due: 05/18/21

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01306643 Org: User:
Start: 02/28/11 End: 08/31/15 Due: 08/31/16

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02639247 Org: User:
Start: 12/23/15 End: 01/18/17 Due: 01/18/18

Expanded Access for IMMU-132

Phase: N/A Priority: Normal
NCT ID: NCT04320693 Org: User:
Start: - End: - Due: -

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Phase: N/A Priority: Normal
NCT ID: NCT04143594 Org: User:
Start: 11/22/19 End: 09/19/23 Due: 09/19/24

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Phase: N/A Priority: Normal
NCT ID: NCT03180619 Org: User:
Start: 06/29/17 End: 09/04/20 Due: 09/04/21

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02864381 Org: User:
Start: 09/01/16 End: 08/23/19 Due: 08/23/20

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01495702 Org: User:
Start: 12/31/11 End: 12/31/14 Due: 12/31/15

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT06630286 Org: User:
Start: 10/09/24 End: 08/31/30 Due: 08/31/31

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00158730 Org: User:
Start: 04/30/03 End: 01/31/05 Due: 01/31/06

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT04060147 Org: User:
Start: 10/17/19 End: 09/02/21 Due: 09/02/22

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01817985 Org: User:
Start: 03/31/13 End: 08/31/13 Due: 08/31/14

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Phase: N/A Priority: Normal
NCT ID: NCT02739360 Org: User:
Start: 05/04/16 End: 12/28/17 Due: 12/28/18

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02077465 Org: User:
Start: 03/11/14 End: 10/27/14 Due: 10/27/15

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Phase: N/A Priority: Normal
NCT ID: NCT00298350 Org: User:
Start: 02/28/06 End: 07/31/07 Due: 07/31/08

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02520284 Org: User:
Start: 09/30/15 End: 11/30/16 Due: 11/30/17

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02010255 Org: User:
Start: 01/31/14 End: 08/31/15 Due: 08/31/16

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT06727565 Org: User:
Start: 02/18/25 End: 08/31/26 Due: 08/31/27

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Phase: N/A Priority: Normal
NCT ID: NCT04891770 Org: User:
Start: 08/14/21 End: 07/19/24 Due: 07/19/25

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

Phase: N/A Priority: Normal
NCT ID: NCT00734162 Org: User:
Start: 12/31/08 End: 12/31/15 Due: 12/31/16

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT01831427 Org: User:
Start: 03/28/13 End: 02/06/15 Due: 02/06/16

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Phase: N/A Priority: Normal
NCT ID: NCT03134222 Org: User:
Start: 05/24/17 End: 12/18/19 Due: 12/18/20